This article has been updated from a previous version to include comments from Qiagen CEO Peer Schatz made during an earnings call.

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Wednesday that its third quarter revenues declined 7 percent year over year largely due to negative currency effects as the firm missed analysts' estimates on the top and bottom lines.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.